ERBB2 and breast carcinoma: This result is in agreement with a recent study done by Thorsson et al. where they showed 60.5% Basal-like breast cancer displayed an IFNγ immune response signature, whereas only 22.8% of Luminal A, 46.6% of Luminal B, 49.3% of Her2 and 33.3% of normal-like patients displayed this signature [61].